Regencell Bioscience faces shareholder class action over alleged stock manipulation risks

• A class action lawsuit was filed on behalf of Regencell Bioscience investors who bought securities from Oct. 28, 2024 to Oct. 31, 2025.
• The suit targets disclosures tied to the company’s trading volatility, citing a valuation that reached about $14 billion despite zero revenue, 12 employees, and about $1 million a year in R&D spend.
• Shares fell $3.09, or 18.56%, to $13.56 on Nov. 3, 2025 following disclosure of a U.S. Department of Justice subpoena tied to an investigation into trading in its ordinary shares.
• The complaint points to a rapid run-up that peaked at $78 on June 17, 2025, followed by a steep decline, then a further selloff tied to the DOJ disclosure.
• The lead plaintiff deadline is June 23, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regencell Bioscience Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605210900PR_NEWS_USPR_____NY64623) on May 21, 2026, and is solely responsible for the information contained therein.